INmune Bio – Helping Your Own Cells Fight Cancer And Reverse Alzheimer's Disease

David Moss, CEO of INmune Bio INMB was recently a guest on Benzinga’s All-Access.

INmune is a clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. INKmune, the company’s lead product, primes patients’ NK cells (natural killer cells) to kill cancer. 

The company is also developing XPro, a therapy for dementia including Alzheimer’s disease. XPro has shown promising results in clinical trials, helping the brain heal itself.

Watch the full interview here:

Investor Contact:

Tyler Troup

Circadian Group IR

Featured photo by Hal Gatewood on Unsplash.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechInterviewGeneralBenzinga All AccessINmune Bio
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!